Adents and Microsoft pool resources to create new cloud platform
pharmafile | October 27, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Adents, EU, France, Microsoft
Adents, a French software developer for unique production identification and ‘Track & Trace’ solutions, and Microsoft have developed, with an aim to commercialisation, a new cloud platform named Adents Prodigi. Adents Prodigi is the only Level 4 traceability solution that can centrally manage regulatory requirements upon the pharmaceutical industry. The platform also allows laboratories and CMOs to access the data generated during the serialisation and Track & Trace process.
The aim of the product is to improve upon unit identification and traceability; fight against the rise of counterfeit medicines, monitor productivity across production sites; enhance user experience and personalise communication whilst providing real-time data visualisation and analysis. The program relies on Microsoft Azure technologies and allows manufactures to securely generate, exchange and control the data that is create through unit identification.
“Our alliance with the leader of Business Intelligence will be a game changer on the global market for unit identification. Indeed, this will finally give the pharmaceutical industry the means to tap into the full potential of the wealth of information generated through serialization,” said Christophe Devins, founder and CEO of Adents.
“We are pleased qu’Adents chose the Microsoft AZURE platform to develop its solution and manage large masses of data generated during the life cycle of a product. Microsoft’s cloud platform will promote the secure deployment of the solution ADENTS internationally, which will accelerate the fight against industrial counterfeiting.” Commented Bernard Ourghanlian , technical and security director of Microsoft France, upon the announcement.
Ben Hargreaves
Related Content
Sharp invests $100m in US and EU manufacturing and packaging facilities
Sharp Services, a pharmaceutical packaging and sterile manufacturing specialist, has announced investments totalling $100m across …
Sarclisa recommended for EU approval in newly diagnosed multiple myeloma
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi’s …
EU approval granted for rare kidney disease treatment
The EU has granted marketing authorisation (MA) for Filspari – CSL Vifor and Travere Therapeutics’ …
